PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. The company is headquartered in Baar, Zug and currently employs 1,366 full-time employees. The company went IPO on 2021-04-29.